PE20141684A1 - Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas - Google Patents
Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanasInfo
- Publication number
- PE20141684A1 PE20141684A1 PE2014000097A PE2014000097A PE20141684A1 PE 20141684 A1 PE20141684 A1 PE 20141684A1 PE 2014000097 A PE2014000097 A PE 2014000097A PE 2014000097 A PE2014000097 A PE 2014000097A PE 20141684 A1 PE20141684 A1 PE 20141684A1
- Authority
- PE
- Peru
- Prior art keywords
- pyrphenidone
- pharmaceutical composition
- procedure
- manufacture
- regression
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 206010019668 Hepatic fibrosis Diseases 0.000 title 1
- 206010062575 Muscle contracture Diseases 0.000 title 1
- 210000000481 breast Anatomy 0.000 title 1
- 208000020832 chronic kidney disease Diseases 0.000 title 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 title 1
- 208000006111 contracture Diseases 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 230000006835 compression Effects 0.000 abstract 1
- 238000007906 compression Methods 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 235000012239 silicon dioxide Nutrition 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
Abstract
SE REFIERE A UN PROCEDIMIENTO PARA LA FABRICACION DE UNA COMPOSICION FARMACEUTICA, QUE COMPRENDE: PASO 1). PIRFENIDONA Y DIOXIDO DE SILICIO SE TAMIZAN POR MALLA No. 30 EN UN GRANULADOR OSCILANTE, LUEGO SE COLOCAN EN UN MEZCLADOR DE LISTON Y MEZCLAR DURANTE 5 MINUTOS; PASO 2). LA CELULOSA MICROCRISTALINA, LAS HIDROXIPROPILMETILCELULOSAS (HPMC) DE BAJA VISCOSIDAD Y DE ALTA VISCOSIDAD SE TAMIZAN EN EL GRANULADOR OSCILANTE, SE COLOCAN EN EL MEZCLADOR DE LISTON DEL PASO 1 Y SE MEZCLAN DURANTE 15 MINUTOS; PASO 3). EL ESTEARIL FUMARATO DE SODIO SE TAMIZA EN EL GRANULADOR OSCILANTE, SE COLOCA EN EL MEZCLADOR DE LISTON DEL PASO 1 Y SE MEZCLA DURANTE 3 MINUTOS; Y PASO 4). EL GRANULADO OBTENIDO SE TABLETEA EN LA TABLETEADORA, PROVISTA DE PUNZONES DE FORMA OBLONDA CON LOS SIGUIENTES PARAMETROS DE COMPRESION: PESO PROMEDIO: 850MG + 5%; DUREZA: MAXIMO 10KG F; FRIABILIDAD: MENOR AL 1%. DICHA COMPOSICION FARMACEUTICA SE PRESENTA EN FORMA DE TABLETAS QUE COMPRENDE 100mg, 200mg, 400mg O 600mg DE PIRFENIDONA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2011007675A MX2011007675A (es) | 2011-07-19 | 2011-07-19 | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20141684A1 true PE20141684A1 (es) | 2014-11-13 |
Family
ID=46940567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014000097A PE20141684A1 (es) | 2011-07-19 | 2012-07-13 | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas |
Country Status (34)
Country | Link |
---|---|
US (6) | US9408836B2 (es) |
EP (2) | EP2735306A1 (es) |
JP (1) | JP6034380B2 (es) |
KR (2) | KR20160074016A (es) |
CN (2) | CN103957892A (es) |
AR (1) | AR087205A1 (es) |
AU (1) | AU2012284627B2 (es) |
BR (1) | BR112014001297B1 (es) |
CA (1) | CA2842654C (es) |
CL (1) | CL2014000131A1 (es) |
CO (1) | CO6970587A2 (es) |
CR (1) | CR20140019A (es) |
CY (2) | CY2200005T2 (es) |
DE (1) | DE15161929T1 (es) |
DK (1) | DK2907506T3 (es) |
DO (1) | DOP2014000010A (es) |
EC (1) | ECSP14013160A (es) |
ES (1) | ES2550227T3 (es) |
HK (1) | HK1208172A1 (es) |
HR (1) | HRP20180183T1 (es) |
HU (1) | HUE036511T2 (es) |
LT (1) | LT2907506T (es) |
MX (1) | MX2011007675A (es) |
NO (1) | NO2907506T3 (es) |
PE (1) | PE20141684A1 (es) |
PL (1) | PL2907506T3 (es) |
PT (1) | PT2907506T (es) |
RS (1) | RS56858B1 (es) |
RU (1) | RU2682177C2 (es) |
SI (1) | SI2907506T1 (es) |
UA (1) | UA114181C2 (es) |
UY (1) | UY34190A (es) |
WO (1) | WO2013012307A1 (es) |
ZA (1) | ZA201400386B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
KR102237799B1 (ko) | 2012-11-14 | 2021-04-08 | 더블유.알. 그레이스 앤드 캄파니-콘. | 생물학적 활성 물질 및 비-정렬된 무기 산화물을 함유하는 조성물 |
CA2943363A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
CA2937365C (en) * | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
CN105997302A (zh) * | 2016-07-18 | 2016-10-12 | 青岛三帝生物科技有限公司 | 基于3d打印的防包膜挛缩乳房假体制作方法和乳房假体 |
MX364040B (es) * | 2016-11-11 | 2019-04-11 | Cell Therapy And Tech S A De C V | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
KR20180100869A (ko) * | 2017-03-02 | 2018-09-12 | 영진약품 주식회사 | 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법 |
CN107080741A (zh) * | 2017-04-28 | 2017-08-22 | 北京工业大学 | 吡非尼酮缓释制剂及制备方法 |
MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
US10980747B2 (en) * | 2017-11-27 | 2021-04-20 | Shin-Etsu Chemical Co., Ltd. | Composition for solid preparation, solid preparation, and method for producing the same |
EP3511001B1 (en) | 2018-01-12 | 2021-09-22 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pirfenidone-containing tablet and capsule formulation |
BR112020021412A8 (pt) | 2018-04-23 | 2022-07-05 | Taiwan Liposome Co Ltd | Composição lipossômica, inalável de liberação prolongada para uso no tratamento de doenças pulmonares |
WO2020115774A1 (en) * | 2018-12-06 | 2020-06-11 | Cipla Limited | High drug load extended release formulations |
KR102199415B1 (ko) | 2019-02-18 | 2021-01-06 | 충북대학교 산학협력단 | 중합체 및 채널링제를 포함하는 피르페니돈 또는 이의 약학적으로 허용가능한 염의 지연 방출용 정제 |
MX2022012986A (es) * | 2020-04-14 | 2023-03-21 | Excalibur Pharmaceuticals Inc | Pirfenidona para el tratamiento del coronavirus. |
WO2021215856A1 (ko) * | 2020-04-22 | 2021-10-28 | 영진약품 주식회사 | 안전성과 안정성이 개선된 피르페니돈을 포함하는 장용성 제제 및 이의 제조방법 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
DE2366349C2 (de) | 1972-12-18 | 1986-03-27 | Affiliated Medical Research Inc., Princeton, N.J. | Verfahren zur Herstellung von 5-Methyl-1-phenyl-2-(1H)-pyridon |
CA1049411A (en) | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | N-substituted pyridone and general method for preparing pyridones |
US3839346A (en) | 1972-12-18 | 1974-10-01 | Affiliated Med Res | N-substituted pyridone and general method for preparing pyridones |
US4105782A (en) | 1975-03-07 | 1978-08-08 | Yu Ruey J | Treatment of acne and dandruff |
JPS51128438A (en) | 1975-04-26 | 1976-11-09 | Yamanouchi Pharmaceut Co Ltd | An antibacterial drug against fish diseases |
SE430609B (sv) | 1976-12-21 | 1983-11-28 | Sca Development Ab | Sett att ur cellulosaderivat framstella absorberande material |
US4376118A (en) | 1980-10-06 | 1983-03-08 | Miles Laboratories, Inc. | Stable nonaqueous solution of tetracycline salt |
SU1719047A1 (ru) * | 1989-11-09 | 1992-03-15 | Воронежский инженерно-строительный институт | Вибрационный гранул тор |
US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
ES2082723B1 (es) * | 1994-07-20 | 1996-10-01 | Lilly Sa | Formulacion farmaceutica de fluoxetina en forma dispersable. |
CZ293747B6 (cs) | 1995-12-21 | 2004-07-14 | Pfizer Inc. | Vodný farmaceutický roztok vhodný pro injekční podávání hostiteli a jeho použití |
US5958420A (en) | 1997-03-13 | 1999-09-28 | Nortrade Medical, Inc. | Treatment of burns, cuts, and abrasions of the skin |
US6365131B1 (en) | 1997-10-31 | 2002-04-02 | J. B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic |
CA2322994A1 (en) | 1998-03-17 | 1999-09-23 | Solomon B. Margolin | Topical antiseptic compositions and methods |
GB9810949D0 (en) | 1998-05-22 | 1998-07-22 | Hewlett Healthcare Limited | Formulation |
DE69810518D1 (de) | 1998-09-18 | 2003-02-06 | Mepha Ag Aesch | Topisch verabreichbare alkyl-, phenyl-pyridone-arzneimittel |
US6277407B1 (en) * | 1998-11-10 | 2001-08-21 | Frederick S. Marius | Apparatus and method for tablet fabrication |
HUP0104606A3 (en) * | 1998-12-18 | 2003-01-28 | Basf Ag | A pharmaceutical mixture comprising a profen |
IN191090B (es) | 2000-08-29 | 2003-09-20 | Ranbanx Lab Ltd | |
EP1356816B1 (en) * | 2001-01-29 | 2009-12-23 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
WO2004073713A1 (ja) | 2003-02-21 | 2004-09-02 | Shionogi & Co., Ltd. | ピルフェニドンのゲル剤 |
EP1638625A4 (en) | 2003-05-23 | 2009-08-19 | David M Ott | ORGANOSOUFRES PROMEDICAMENTS FOR PREVENTING AND TREATING INFECTIOUS DISEASES AND A PATHOLOGICAL REACTION OF THE IMMUNE SYSTEM |
US20080025986A1 (en) | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
US8168228B2 (en) * | 2003-10-17 | 2012-05-01 | Sandoz Ag | Antibiotic clarithromycin micropellet compositions |
US20060051339A1 (en) | 2004-09-08 | 2006-03-09 | Sivak Hannah N | Composition for treatment of oily skin and acne prevention and methods of making and using same |
US20060115503A1 (en) | 2004-11-30 | 2006-06-01 | Goyal Muna C | Composition, system and method for treatment of skin |
NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
US20070203202A1 (en) * | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
CA2631497C (en) | 2005-12-05 | 2014-04-22 | Bioartificial Gel Technologies Inc. | Emulsions of a protein-crosslinked hydrogel matrix and dispersed hydrophobic phase |
US20080050449A1 (en) * | 2006-03-21 | 2008-02-28 | Dafna Arieli | Controlled release formulation of tolterodine |
ATE533486T1 (de) * | 2006-06-15 | 2011-12-15 | Shanghai Genomics Inc | Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung |
ATE506060T1 (de) * | 2006-12-18 | 2011-05-15 | Intermune Inc | Verfahren zur bereitstellung einer pirfenidontherapie an einem patienten |
JP2010520194A (ja) | 2007-03-02 | 2010-06-10 | ミロン、タリア | 抗癌剤としてのメルカプトプリン誘導体 |
MX2007006347A (es) * | 2007-05-29 | 2009-02-18 | Cell Therapy And Technology S | Nuevo uso de 5-metil-1-fenil-2-(1h)-piridona para el tratamiento y prevencion de cicatrices hipertroficas, y composicion conteniendo la misma. |
EP2170828B1 (en) * | 2007-06-20 | 2012-11-21 | Auspex Pharmaceuticals, Inc. | Substituted n-aryl pyridinones as fibrotic inhibitors |
MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
CN101244045B (zh) * | 2007-12-21 | 2010-06-30 | 东华大学 | 一种零级给药口服控释片剂及其制备方法 |
CN101972236A (zh) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的缓释制剂 |
MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
MX352342B (es) | 2013-07-12 | 2017-11-22 | Moleculas Naturales S A De C V Star | Un procedimiento para fabricar un complejo mejorado de cloruro de bencetonio-dialil oxido de disulfuro modificado, el complejo obtenido y sus usos. |
MX364040B (es) | 2016-11-11 | 2019-04-11 | Cell Therapy And Tech S A De C V | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
-
2011
- 2011-07-19 MX MX2011007675A patent/MX2011007675A/es active IP Right Grant
-
2012
- 2012-07-09 UY UY0001034190A patent/UY34190A/es active IP Right Grant
- 2012-07-13 EP EP12766487.8A patent/EP2735306A1/en not_active Withdrawn
- 2012-07-13 US US14/233,600 patent/US9408836B2/en active Active
- 2012-07-13 CN CN201280045648.XA patent/CN103957892A/zh active Pending
- 2012-07-13 BR BR112014001297-0A patent/BR112014001297B1/pt active IP Right Grant
- 2012-07-13 LT LTEP15161929.3T patent/LT2907506T/lt unknown
- 2012-07-13 EP EP15161929.3A patent/EP2907506B1/en active Active
- 2012-07-13 SI SI201231198T patent/SI2907506T1/en unknown
- 2012-07-13 WO PCT/MX2012/000067 patent/WO2013012307A1/es active Application Filing
- 2012-07-13 PL PL15161929T patent/PL2907506T3/pl unknown
- 2012-07-13 KR KR1020167015898A patent/KR20160074016A/ko not_active Application Discontinuation
- 2012-07-13 DE DE15161929.3T patent/DE15161929T1/de active Pending
- 2012-07-13 UA UAA201401623A patent/UA114181C2/uk unknown
- 2012-07-13 KR KR1020147002065A patent/KR101632332B1/ko active IP Right Grant
- 2012-07-13 JP JP2014521581A patent/JP6034380B2/ja active Active
- 2012-07-13 NO NO15161929A patent/NO2907506T3/no unknown
- 2012-07-13 PE PE2014000097A patent/PE20141684A1/es active IP Right Grant
- 2012-07-13 CA CA2842654A patent/CA2842654C/en active Active
- 2012-07-13 RU RU2014101231A patent/RU2682177C2/ru not_active Application Discontinuation
- 2012-07-13 RS RS20180168A patent/RS56858B1/sr unknown
- 2012-07-13 AU AU2012284627A patent/AU2012284627B2/en active Active
- 2012-07-13 DK DK15161929.3T patent/DK2907506T3/en active
- 2012-07-13 PT PT15161929T patent/PT2907506T/pt unknown
- 2012-07-13 CN CN202011071995.2A patent/CN112386579A/zh active Pending
- 2012-07-13 ES ES15161929.3T patent/ES2550227T3/es active Active
- 2012-07-13 HU HUE15161929A patent/HUE036511T2/hu unknown
- 2012-07-16 AR ARP120102578A patent/AR087205A1/es not_active Application Discontinuation
-
2014
- 2014-01-16 CR CR20140019A patent/CR20140019A/es unknown
- 2014-01-17 ZA ZA2014/00386A patent/ZA201400386B/en unknown
- 2014-01-17 CO CO14008053A patent/CO6970587A2/es unknown
- 2014-01-17 CL CL2014000131A patent/CL2014000131A1/es unknown
- 2014-01-20 DO DO2014000010A patent/DOP2014000010A/es unknown
- 2014-01-21 EC ECSP14013160 patent/ECSP14013160A/es unknown
-
2015
- 2015-09-10 HK HK15108824.8A patent/HK1208172A1/xx unknown
- 2015-12-16 CY CY20152200005T patent/CY2200005T2/el unknown
-
2016
- 2016-06-09 US US15/177,760 patent/US9962374B2/en active Active
-
2017
- 2017-12-05 US US15/831,650 patent/US10383862B2/en active Active
-
2018
- 2018-01-31 HR HRP20180183TT patent/HRP20180183T1/hr unknown
- 2018-02-05 CY CY20181100141T patent/CY1119886T1/el unknown
-
2019
- 2019-07-02 US US16/460,407 patent/US11040030B2/en active Active
- 2019-08-19 US US16/544,643 patent/US11052074B2/en active Active
-
2021
- 2021-06-17 US US17/351,151 patent/US20210386724A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20141684A1 (es) | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas | |
AR081774A1 (es) | Composiciones farmaceuticas de co-cristales de tramadol y coxibs | |
AR065096A1 (es) | Preparacion solida | |
CR20170361A (es) | Forma de dosificación que incluye una solución sólida de drogas amorfas | |
PE20180522A1 (es) | Unidad de dosificacion orodispersable que contiene un componente estetrol | |
CO6460753A2 (es) | Procedimiento y composición para mejorar la absorción de agentes terapéuticos | |
MY174005A (en) | Swallowable n-acetylcysteine tablets | |
AR081902A1 (es) | Comprimidos de meloxicam de baja concentracion | |
ES2582309T3 (es) | Uso de trinitrato de glicerilo para el tratamiento de edema traumático | |
EA201591568A1 (ru) | Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения | |
TW201129386A (en) | Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients | |
EA202090913A1 (ru) | Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон | |
EA201990129A1 (ru) | Таблетированный состав с улучшенным профилем растворения для лечения болезни паркинсона | |
CO2018010142A2 (es) | Proceso de preparación de fórmulas solidas de mesalazina | |
GT201400044A (es) | 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticos | |
HRP20210969T1 (hr) | Farmaceutski sastav koji sadrži darunavir i metoda za njegovu pripremu | |
RU2013127794A (ru) | Фармацевтическая комбинация и композиция для лечения ожирения и ее применение | |
RU2014120368A (ru) | Противовирусное лекарственное средство в виде капсул и способ его получения | |
DOP2019000035A (es) | Composición mejorada de teneligliptina y metformina y proceso para prepararla | |
RU2013101117A (ru) | Способ изготовления твердой фармацевтической композиции валсартана и гидрохлортиазида | |
TH164760A (th) | เม็ด n-อะซีติลซิสเทอีนที่สามารถกลืนได้ | |
RU2011109432A (ru) | Фармацевтическая композиция для лечения сердца пролонгированного действия | |
DOP2014000047A (es) | 2-(Croman-6-iloxi)-tiazoles sustituidos y su uso como farmacéuticos | |
TH147179A (th) | กระบวนการสำหรับการเตรียมขององค์ประกอบทางเภสัชกรรมที่บรรจุเพียร์เฟนิโดนในรูปยาเม็ดชนิดปลดปล่อยเนิ่นนาน และการใช้ของสิ่งนั้นในการทุเลาของ ภาวะไตวายเรื้อรัง, ภาวะพังผืดหดรัดของเต้านม, และ ภาวะพังผืดที่ตับของมุนษย์ | |
PL399712A1 (pl) | Sposób wytwarzania tabletki o zwiekszonej dostepnosci farmaceutycznej worykonazolu |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |